Centessa Pharmaceuticals Cost Of Revenue Over Time
| CNTA Stock | USD 17.91 0.31 1.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Centessa Pharmaceuticals Performance and Centessa Pharmaceuticals Correlation. Centessa |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.065 | Return On Assets (0.20) | Return On Equity (0.43) |
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cost Of Revenue Analysis
Compare Centessa Pharmaceuticals and related stocks such as Century Therapeutics, Edgewise Therapeutics, and C4 Therapeutics Cost Of Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPSC | 888.8 M | 888.8 M | 888.8 M | 888.8 M | 888.8 M | 888.8 M | 467.8 M | 249 K | 249 K | 249 K | 1.8 M | 4.6 M | 10.1 M | 13 M | 12.4 M |
| EWTX | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 123 K | 185 K | 272 K | 538 K | 1.7 M | 1.8 M |
| CCCC | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 77.5 M | 2.9 M | 7.6 M | 117.7 M | 123.6 M |
| CGEM | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 70 K | 70 K | 70 K | 62 K | 53 K | 93 K | 310 K | 325.5 K |
| NAMSW | 14.6 K | 14.6 K | 14.6 K | 14.6 K | 14.6 K | 14.6 K | 14.6 K | 14.6 K | 14.6 K | 14.6 K | 14.6 K | 14.6 K | 70.7 K | 44.4 K | 47.5 K |
| STRO | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M | 51.9 M | 54.3 M | 65.6 M | 77 M | 9.8 M | 8.3 M | 6.8 M | 6.5 M |
| OPT | 16.4 K | 23.7 K | 23.7 K | 23.7 K | 23.7 K | 23.7 K | 23.7 K | 23.7 K | 23.7 K | 517.3 K | 572 K | 232.5 K | 250.5 K | 240.1 K | 291.1 K |
| HLVX | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 2.3 M | 2.2 M | 1.6 M |
| TARS | 74 K | 74 K | 74 K | 74 K | 74 K | 74 K | 74 K | 74 K | 74 K | 74 K | 246 K | 2.1 M | 955 K | 1.6 M | 1.1 M |
| GNFT | 1.3 M | 1.4 M | 1.2 M | 1.3 M | 1.4 M | 1.9 M | 2 M | 2.2 M | 1.9 M | 202 K | 202 K | 161 K | 248 K | 341 K | 323.9 K |
| GLUE | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 72 K | 537 K | 2.1 M | 8.6 M | 6.2 M | 3.9 M |
| DSGN | 1.7 K | 1.7 K | 1.7 K | 1.7 K | 1.7 K | 1.7 K | 1.7 K | 1.7 K | 1.7 K | 1.7 K | 5 K | 129 K | 466 K | 537 K | 563.9 K |
| ERAS | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 310 K | 540 K | 829 K | 2.6 M | 3.7 M | 3.9 M |
| CRNX | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 9.2 M | 24.5 M | 41.5 M | 57 M | 1.3 M | 1.4 M | 1.1 M | 1 M |
| TRDA | 104 K | 104 K | 104 K | 104 K | 104 K | 104 K | 104 K | 104 K | 104 K | 104 K | 326 K | 1.1 M | 1.9 M | 99.9 M | 104.9 M |
| IRON | 322 K | 322 K | 322 K | 322 K | 322 K | 322 K | 322 K | 322 K | 322 K | 322 K | 322 K | 192 K | 300 K | 100 K | 182.8 K |
| LRMR | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 212 K | 188 K | 261 K | 78 K | 155 K | 326 K | 272 K | 311 K | 228.9 K |
Centessa Pharmaceuticals and related stocks such as Century Therapeutics, Edgewise Therapeutics, and C4 Therapeutics Cost Of Revenue description
Cost of Revenue is found on Centessa Pharmaceuticals income statement and represents the costs associated with goods and services Centessa Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.My Equities
My Current Equities and Potential Positions
| Centessa Pharmaceuticals PLC | CNTA |
| Classification | Biotech |
| Location | United Kingdom |
| Exchange | NASDAQ Exchange |
USD 17.91
Check out Centessa Pharmaceuticals Performance and Centessa Pharmaceuticals Correlation. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Centessa Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.